|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Hydralazine#Warnings]] |
| {{Hydralazine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==WARNINGS==
| |
| | |
| In a few patients hydralazine may produce a clinical picture simulating [[systemic lupus erythematosus]] including [[glomerulonephritis]]. In such patients hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See [[Hydralazine tablet precautions|PRECAUTIONS, Laboratory Tests]].)<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE TABLET [PLIVA INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddbbdb09-3202-42d7-bbb0-08331dde2f54 | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |